Reflections on the effects of nitric oxide produced by a new dressing in the local management of diabetic foot ulcers

A diabetic foot ulcer (DFU) precedes 75–85% of amputations in people with diabetes (1). The estimated global prevalence of DFU is 6.3% (2), with a lifetime incidence between 19% and 34% in people with diabetes. Nonhealing ulcers increase the probability of infection and amputation, which severely decrease life expectancy and increase costs. The treatment of diabetic foot complications reportedly may exceed the treatment costs of many common cancers (3).